智通财经网·2026-02-02 03:13Core Viewpoint - The report from China Merchants Securities International highlights a historic deal between CSPC Pharmaceutical Group (01093) and AstraZeneca (AZN.US), expressing optimism about the transaction but indicating the need for further details on the long-acting GLP-1 global development from either CSPC or AstraZeneca [1] Group 1: Transaction Details - CSPC's key clinical candidate in collaboration with AstraZeneca is SYH2082, a long-acting GLP-1R/GIPR dual agonist, which has entered Phase I clinical trials [1] - The report notes that there is limited understanding of the long-acting GLP-1 platform, as SYH2082 has just initiated Phase I research in China [1] Group 2: Investment Outlook - The firm maintains a "neutral" rating, citing short-term fundamental concerns despite a long-term positive outlook on "Chinese innovative drugs entering the global pipeline" [1] - Investors are advised to carefully examine the asset valuation factors that may have already been priced in by the market prior to the business development announcement [1] Group 3: Market Competition - The entry of siRNA into the obesity maintenance market poses a significant threat to all peptide-based solutions [1] - The report emphasizes that siRNA drugs targeting weight loss and muscle preservation may ultimately pressure peptide-based obesity therapies, with a focus on the progress of Arrowhead and Wave siRNA assets [1] - Investors are encouraged to monitor the future impact of siINHBE and siALK7 targets on the weight maintenance market [1]